TP53 and cancer: Second, integration of bulk RNA-seq data from the TCGA NSCLC cohort uncovered cell subsets associated with alterations in major driver genes, such as EGFR, KRAS, STK11, and TP53, in both LUAD and LUSC subtypes, providing further evidence that genetic aberrations in cancer cells dictate the immune contexture of tumors.48